Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC) (NCT06898957)
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With YL201 With or Without Anti-PD-L1 in Subjects With Extensive Stage Small Cell Lung Cancer
🩺 Plain-English Summary (8th-Grade Level)
The primary objective of this study is to evaluate the safety and tolerability of tarlatamab in combination with YL201 with or without anti-PD-L1.
Who can join: Review the eligibility criteria below.
Location: City of Hope Orange County Lennar Foundation Cancer Center — Irvine, California
Age range: 18 Years to 99 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (36 Sites)
Showing the first 25 of 36 sites.
- City of Hope Orange County Lennar Foundation Cancer Center — Irvine, California
- Yale New Haven Hospital — New Haven, Connecticut
- Moffitt Cancer Center — Tampa, Florida
- Dana Farber Cancer Institute — Boston, Massachusetts
- Siteman Cancer Center — St Louis, Missouri
- Sanford Roger Maris Cancer Center — Fargo, North Dakota
- Cleveland Clinic Foundation — Cleveland, Ohio
- Sanford Oncology Clinic and Pharmacy — Sioux Falls, South Dakota
- University of Texas MD Anderson Cancer Center — Houston, Texas
- Swedish Medical Center — Seattle, Washington
- Fred Hutchinson Cancer Center — Seattle, Washington
- CHU de Quebec Hopital de l Enfant Jesus — Québec, Quebec
- Shandong Cancer Hospital — Jinan, Shandong
- West China Hospital of Sichuan University — Chengdu, Sichuan
- Fujian Cancer Hospital — Fuzhou,
- Institut Bergonie — Bordeaux,
- Centre Leon Berard — Lyon,
- Institut Universitaire du Cancer Toulouse Oncopole — Toulouse,
- Gustave Roussy — Villejuif,
- Universitaetsklinikum Essen — Essen,
- Henry Dunant Hospital Center — Athens,
- Alexandra Hospital — Athens,
- European Interbalkan Medical Center — Thessaloniki,
- Iatriko Diavalkaniko Thessalonikis — Thessaloniki,
- Semmelweis Egyetem — Budapest,
📞 Contact the Study Coordinator
Phone: (800) 826-4673
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Small Cell Lung Cancer
- Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Chemotherapy — New Haven, Connecticut
- Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013) — Chandler, Arizona
- Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy — Tucson, Arizona
- Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms — Rockville, Maryland
- PF-07104091 as a Single Agent and in Combination Therapy — Clive, Iowa
Explore by condition: All Small Cell Lung Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.